OBJECTIVE: We conducted an ex-vivo analysis and a study in healthy subjects to compare magnesium bioavailability after administration of Sucrosomial (R) magnesium or commercially available preparations of magnesium citrate, magnesium oxide and magnesium bisglycinate. MATERIALS AND METHODS: In the ex-vivo study we simulated magnesium intestinal absorption after digestion through sections of intestinal mucosa isolated from rats. We compared the absorption of magnesium oxide and Sucrosomial (R) magnesium at two different concentrations: 32.9 mg/ml and 329 mg/ml. The human study was a single day double-blinded repeated crossover study in healthy subjects. Each subject was administered 350 mg magnesium in different formulations (Sucrosomial (R) magnesium, magnesium citrate, magnesium oxide or magnesium bisglycinate) after 1 week of washout. We collected blood and urine samples to measure magnesium concentration in blood, urine and red blood cells. RESULTS: The ex-vivo evaluation showed that magnesium absorption after administration of Sucrosomial (R) magnesium was faster and with higher rates compared to a standard formulation of magnesium oxide. This finding was further confirmed by the results of the study in healthy subjects, that showed a more evident increase in magnesium concentration after administration of Sucrosomial (R) magnesium compared to the other formulations. In particular, the increase in magnesium concentration from baseline to 24 h was statistically higher in blood and in urine for Sucrosomial (R) magnesium compared to magnesium oxide, while in red blood cells Sucrosomial (R) magnesium had a statistically significant advantage compared to magnesium bisglycinate. CONCLUSIONS: Our findings suggest that Sucrosomial (R) magnesium leads to an increased bioavailability of magnesium compared to other formulations. Further studies are needed to investigate if this advantage turns into more evident clinical efficacy.
Magnesium bioavailability after administration of sucrosomial (R) magnesium: results of an ex-vivo study and a comparative, double-blinded, cross-over study in healthy subjects
A. Fabiano;Y. Zambito;
2018-01-01
Abstract
OBJECTIVE: We conducted an ex-vivo analysis and a study in healthy subjects to compare magnesium bioavailability after administration of Sucrosomial (R) magnesium or commercially available preparations of magnesium citrate, magnesium oxide and magnesium bisglycinate. MATERIALS AND METHODS: In the ex-vivo study we simulated magnesium intestinal absorption after digestion through sections of intestinal mucosa isolated from rats. We compared the absorption of magnesium oxide and Sucrosomial (R) magnesium at two different concentrations: 32.9 mg/ml and 329 mg/ml. The human study was a single day double-blinded repeated crossover study in healthy subjects. Each subject was administered 350 mg magnesium in different formulations (Sucrosomial (R) magnesium, magnesium citrate, magnesium oxide or magnesium bisglycinate) after 1 week of washout. We collected blood and urine samples to measure magnesium concentration in blood, urine and red blood cells. RESULTS: The ex-vivo evaluation showed that magnesium absorption after administration of Sucrosomial (R) magnesium was faster and with higher rates compared to a standard formulation of magnesium oxide. This finding was further confirmed by the results of the study in healthy subjects, that showed a more evident increase in magnesium concentration after administration of Sucrosomial (R) magnesium compared to the other formulations. In particular, the increase in magnesium concentration from baseline to 24 h was statistically higher in blood and in urine for Sucrosomial (R) magnesium compared to magnesium oxide, while in red blood cells Sucrosomial (R) magnesium had a statistically significant advantage compared to magnesium bisglycinate. CONCLUSIONS: Our findings suggest that Sucrosomial (R) magnesium leads to an increased bioavailability of magnesium compared to other formulations. Further studies are needed to investigate if this advantage turns into more evident clinical efficacy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
